Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
Philip C MackRachel B Keller-EvansGerald LiKatherine T LofgrenAlexa B SchrockSally E TrabuccoJustin M AllenKhaled TolbaGeoffrey R OxnardRichard S P HuangPublished in: The oncologist (2024)
A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.